Compare Repligen Corporation Common Stock (RGEN) vs Southern Company (SO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Southern Company — how do they compare? Repligen Corporation Common Stock trades at $178.18 (market cap $11.14B), while Southern Company trades at $89.8 (market cap $101.36B). The key difference: Southern Company is far larger — about 9.1× Repligen Corporation Common Stock's market cap, and Southern Company pays a 3.45% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Southern Company for 17 Days on average.
| RGEN | SO | |
|---|---|---|
Market Cap | $11.14B | $101.36B |
Volume | 1,259,263 | 6,566,089 |
Sector | Health | Utilities |
52-Week High | $194.57 | $99.72 |
52-Week Low | $102.87 | $82.35 |
Typical Hold Time | 0 Days | 17 Days |
Enterprise Value | $11.02B | $175.46B |
Dividend Yield | — | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Southern Company (SO) trades at $88.11, up 1.23% on the day, with a mixed technical outlook showing a bullish overall signal but bearish oscillators. The company reported strong Q1 and Q2 2026 earnings beats, with Q3 2026 results pending. Revenue and net income are projected to grow in 2026, supported by a 15.43% net income margin. Analyst sentiment is cautious with a 32.35% buy rating, but the consensus price target of $96.38 suggests upside potential. Recent news highlights data center demand and dividend stability, though near-term cash flow pressure from high capital expenditures is a concern.
The outlook for SO is balanced, with long-term growth driven by utility demand and data center contracts, but near-term risks include capital expenditure pressures and potential data breach impacts. The stock offers a stable dividend and is positioned for gradual appreciation if earnings continue to outperform, yet investors should monitor cash flow trends and regulatory developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Southern Company
Southern Company is a U.S. energy company with electric and gas utility businesses. Its power generation portfolio includes natural gas, nuclear, renewable, and other energy sources.
Read more on SO →
